A review of trazodone use in psychiatric and medical conditions

References

• Fabre LF. United States experience and perspectives with trazodone. Clin Neuropharmacol. 1989;12:11–17.
   Web of Science ®Google Scholar
• Stahl SM. Essential psychopharmacology: neuroscientific basis and practical applications (Ed. 3). New York (NY): Cambridge University Press; 2008.
   Google Scholar
• Bossini L, Casolaro I, Koukouna D, et al. Off-label uses of trazodone: a review. Expert Opin Pharmacother. 2012;13:1707–1717.
   PubMed Web of Science ®Google Scholar
• Fagiolini A, Comandini A, Catena Dell’Osso M, et al. Rediscovering trazodone for the treatment of major depressive disorder. CNS Drugs. 2012;26:1033–1049.
   PubMed Web of Science ®Google Scholar
• Kraus RL, Li Y, Jovanovska A, et al. Trazodone inhibits T-type calcium channels. Neuropharmacology. 2007;53:308–317.
   PubMed Web of Science ®Google Scholar
• Khouzam HR. The antidepressant nefazodone: a review of its pharmacology, clinical efficacy, adverse effects, dosage and administration. Psychosocial Nurs Ment Health Ser. 2000;38:20–25.
   PubMedGoogle Scholar
• Khouzam HR. Vilazodone for the treatment of paternal post natal depression. Clin Depress. 2015;1:1.
   Google Scholar
• Zhang L, Xie WW, Li LH, et al. Efficacy and safety of prolonged-release trazodone in major depressive disorder: a multicenter, randomized, double-blind, flexible-dose trial. Pharmacology. 2014;94:199–206.
   PubMed Web of Science ®Google Scholar
• Kale P, Agrawal YK. Pharmacokinetics of single oral dose trazodone: a randomized, two-period, cross-over trial in healthy, adult, human volunteers under fed condition. Front Pharmacol. 2015;6:224.
   PubMed Web of Science ®Google Scholar
• Jauch R, Kopitar Z, Prox A, et al. Pharmacokinetics and metabolism of trazodone in man (author’s transl). Arzneimittelforschung (In German). 1976;26:2084–2089.
   PubMed Web of Science ®Google Scholar
• Rotzinger S, Fang J, Baker GB, et al. Trazodone is metabolized to m-chlorophenylpiperazine by CYP3A4 from human sources. Drug Metab Dispos. 1998;26:572–575.
   PubMed Web of Science ®Google Scholar
• Ishida M, Otani K, Kaneko S, et al. Effects of various factors on steady state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine. Int Clin Psychopharmacol. 1995;10:143–146.
   PubMed Web of Science ®Google Scholar
• Kahn RS, Wetzler S, Asnis GM, et al. Effects of m-chlorophenylpiperazine in normal subjects: a dose-response study. Psychopharmacology (Berl). 1990;100:339–344.
   PubMed Web of Science ®Google Scholar
• Mihara K, Otani K, Suzuki A, et al. Relationship between the CYP2D6 genotype and the steady-state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine. Psychopharmacology (Berl). 1997;133:95–98.
   PubMed Web of Science ®Google Scholar
• Zalma A, von Moltke LL, Granda BW, et al. In vitro metabolism of trazodone by CYP3A: inhibition by ketoconazole and human immunodeficiency viral protease inhibitors. Biol Psychiatry. 2000;47:655–661.
   PubMed Web of Science ®Google Scholar
• Fang J, Coutts RT, Baker GB. Human CYP2D6 and metabolism of m-chlorophenylpiperazine. Biol Psychiatry. 1998;44:1185–1191.
   PubMed Web of Science ®Google Scholar
• Yasui N, Otani K, Kaneko S, et al. Inhibition of trazodone metabolism by thioridazine in humans. Ther Drug Monit. 1995;17:333–335.
   PubMed Web of Science ®Google Scholar
• Bayer AJ, Pathy MS, Ankier SI. Pharmacokinetic and pharmacodynamic characteristics of trazodone in the elderly. Br J Clin Pharmacol. 1983;16:371–376.
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ, Friedman H, Burstein ES, et al. Trazodone kinetics: effect of age, gender, and obesity. Clin Pharmacol Ther. 1987;42:193–200.
   PubMed Web of Science ®Google Scholar
• Warner MD, Peabody CA, Whiteford HA, et al. Trazodone and priapism. J Clin Psychiatry. 1987;48:244–245.
   PubMed Web of Science ®Google Scholar
• Sood S, James W, Bailon M-J. Priapism associated with atypical antipsychotic medications: a review. Int Clin Psychopharmacol. 2008;23:9–17.
   PubMed Web of Science ®Google Scholar
• Segal RL, Readal N, Pierorazio PM, et al. Corporal burnett “snake” surgical maneuver for the treatment of ischemic priapism: long-term follow up. J Urol. 2013;189:1025–1029.
   PubMed Web of Science ®Google Scholar
• Otani K, Tanaka O, Kaneko S, et al. Mechanisms of the development of trazodone withdrawal symptoms. Int Clin Psychopharmacol. 1994;9:131–133.
   PubMed Web of Science ®Google Scholar
• Gamble DE, Peterson LG. Trazodone overdose: four years of experience from voluntary reports. J Clin Psychiatry. 1986;47:544–546.
   PubMed Web of Science ®Google Scholar
• Martínez MA, Ballesteros S, Sánchez de la Torre C, et al. Investigation of a fatality due to trazodone poisoning: case report and literature review. J Anal Toxicol. 2005;29:262–268.
   PubMed Web of Science ®Google Scholar
• de Meester A, Carbutti G, Gabriel L, et al. Fatal overdose with trazodone: case report and literature review. Acta Clin Belg. 2001;56:258–261.
   PubMed Web of Science ®Google Scholar
• Einarson A, Bonari L, Voyer-Lavigne S, et al. A multicentre prospective controlled study to determine the safety of trazodone and nefazodone use during pregnancy. Can J Psychiatry. 2003;48:106–110.
   PubMed Web of Science ®Google Scholar
• Eberhard-Gran M, Eskild A, Opjordsmoen S. Use of psychotropic medications in treating mood disorders during lactation: practical recommendations. CNS Drugs. 2006;20:187–198.
   PubMed Web of Science ®Google Scholar
• Hansen RN, Boudreau DM, Ebel BE, et al. Sedative hypnotic medication use and the risk of motor vehicle crash. Am J Public Health. 2015;105:e64–e69.
   PubMed Web of Science ®Google Scholar
• Price LH, Charney DS, Heninger GR. Effects of trazodone treatment on alpha-2 adrenoceptor function in depressed patients. Psychopharmacology (Berl). 1986;89:38–44.
   PubMed Web of Science ®Google Scholar
• Small NL, Giamonna KA. Interaction between warfarin and trazodone. Ann Pharmacother. 2000;34:734–736.
   PubMed Web of Science ®Google Scholar
• Smith CJ, Wang D, Sgambelluri A, et al. Serotonin syndrome following methylene blue administration during cardiothoracic surgery. J Pharm Pract. 2015;28:207–211.
   PubMedGoogle Scholar
• Bergeron L, Boulé M, Perreault S. Serotonin toxicity associated with concomitant use of linezolid. Ann Pharmacother. 2005;39:956–961.
   PubMed Web of Science ®Google Scholar
• Jabeen S, Fisher CJ. Trazodone-induced transient hypomanic symptoms and their management. Br J Psychiatry. 1991;158:275–278.
   PubMed Web of Science ®Google Scholar
• Blackmer AB, Feinstein JA. Management of sleep disorders in children with neurodevelopmental disorders: a review. Pharmacotherapy. 2016;36:84–98.
   PubMed Web of Science ®Google Scholar
• Khouzam HR. Depression: guidelines for effective primary care, part 2 treatment. Consultant. 2007;47:841–848.
   Google Scholar
• Greenberg PE, Fournier -A-A, Sisitsky T, et al. The economic burden of adults with major depressive disorder in the United States (2005 and 2010). J Clin Psychiatry. 2015;76:155–162.
   PubMed Web of Science ®Google Scholar
• Papakostas GI, Fava MA. Meta-analysis of clinical trials comparing the serotonin (5HT)-2 receptor antagonists trazodone and nefazodone with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. Eur Psychiatry. 2007;22(7):444–447.
   PubMed Web of Science ®Google Scholar
• Harter M, Klesse C, Bermejo I, et al. Unipolar depression: diagnostic and therapeutic recommendations from the current S3/national clinical practice guideline. Dtsch Arztebl Int. 2010;107:700–708.
   PubMed Web of Science ®Google Scholar
• Poon IO, Braun U. High prevalence of orthostatic hypotension and its correlation with potentially causative medications among elderly veterans. J Clin Pharm Ther. 2005;30:173–178.
   PubMed Web of Science ®Google Scholar
• Gerner R, Estabrook W, Steuer J, et al. Treatment of geriatric depression with trazodone, imipramine, and placebo: a double-blind study. J Clin Psychiatry. 1980;41:216–220.
   PubMed Web of Science ®Google Scholar
• Chong Y, Fryar CD, Gu Q. Prescription sleep aid use among adults: United States, 2005–2010. Hyattsville (MD): National Center for Health Statistics; 2013. NCHS Data Brief No. 127.
   Google Scholar
• Mittur A. Trazodone: properties and utility in multiple disorders. Expert Rev Clin Pharmacol. 2011;4:181–196.
   PubMedGoogle Scholar
• James SP, Mendelson WB. The use of trazodone as a hypnotic: a critical review. J Clin Psychiatry. 2004;65:752–755.
   PubMed Web of Science ®Google Scholar
• Savarese M, Carnicelli M, Cardinali V, et al. Subjective hypnotic efficacy of trazodone and mirtazapine in patients with chronic insomnia: a retrospective, comparative study. Arch Ital Biol. 2015;153:243–250.
   Web of Science ®Google Scholar
• Roth AJ, McCall WV, Liguori A. Cognitive, psychomotor and polysomnographic effects of trazodone in primary insomniacs. J Sleep Res. 2011;20:552–558.
   PubMed Web of Science ®Google Scholar
• Bertisch SM, Herzig SJ, Winkelman JW, et al. National use of prescription medications for insomnia: NHANES 1999-2010. Sleep. 2014;37:343–349.
   PubMed Web of Science ®Google Scholar
• Rosenberg RP. Sleep maintenance insomnia: strengths and weaknesses of current pharmacologic therapies. Ann Clin Psychiatry. 2006;18:49–56.
   PubMedGoogle Scholar
• Mendelson WB. Combining pharmacologic and nonpharmacologic therapies for insomnia. J Clin Psychiatry. 2007;68(Suppl 5):19–23.
   PubMed Web of Science ®Google Scholar
• Wittchen HU, Lieb R, Wunderlich U, et al. Comorbidity in primary care: presentation and consequences. J Clin Psychi- Atry. 1999;60(Suppl7):29–36. discussion 7–8.
   PubMed Web of Science ®Google Scholar
• Gale CK. The treatment of generalised anxiety disorder: a systematic review. Panminerva Med. 2002;44(4):283–286.
   PubMed Web of Science ®Google Scholar
• Mavissakalian M, Perel J, Bowler K, et al. Trazodone in the treatment of panic disorder and agoraphobia with panic attacks. Am J Psychiatry. 1987;144:785–787.
   PubMed Web of Science ®Google Scholar
• Charney DS, Woods SW, Goodman WK, et al. Drug treatment of panic disorder: the comparative efficacy of imipramine, alprazolam, and trazodone. J Clin Psychiatry. 1986;47:580–586.
   PubMed Web of Science ®Google Scholar
• Shiromani PJ, Keane TM, LeDoux JE, editors. Post-traumatic stress disorder: basic science and clinical practice. New York (NY): Humana Press; 2009.
   Google Scholar
• Khouzam HR. Pharmacotherapy for posttraumatic stress disorder. J Clin Outcomes Manag. 2013;20:21–33.
   Google Scholar
• Warner MD, Dorn MR, Peabody CA. Survey on the usefulness of trazodone in patients with PTSD with insomnia or nightmares. Pharmacopsychiatry. 2001;34:128–131.
   PubMed Web of Science ®Google Scholar
• Friedman MJ. PTSD: pharmacotherapeutic approaches. Focus. 2013;11:315–320.
   Google Scholar
• Marazziti D, Gemignani A, Dell’osso L. Trazodone augmentation in OCD: a case series report. CNS Spectr. 1999;4:48–49.
   PubMedGoogle Scholar
• Herpertz-Dahlmann B. Adolescent eating disorders: update on definitions, symptomatology, epidemiology, and comorbidity. Child Adolesc Psychiatr Clin N Am. 2015;24:177–196.
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington (TX): American Psychiatric Publishing; 2013.
   Google Scholar
• Allison KC, Lundgren JD, O’Reardon JP, et al. Proposed diagnostic criteria for night eating syndrome. Int J Eat Disord. 2010;43:241–247.
   PubMed Web of Science ®Google Scholar
• Winkelman JW. Clinical and polysomnographic features of sleep-related eating disorder. J Clin Psychiatry. 1998;59:14–19.
   PubMed Web of Science ®Google Scholar
• Allison KC, Grilo CM, Masheb RM, et al. Binge eating disorder and night eating syndrome: a comparative study of disordered eating. J Consult Clin Psychol. 2005;73:1107–1115.
   PubMed Web of Science ®Google Scholar
• Stunkard AJ, Allison KC. Two forms of disordered eating in obesity: binge eating and night eating. Int J Obes Relat Metab Disord. 2003;27:1–12.
   PubMed Web of Science ®Google Scholar
• Stunkard AJ, Allison KC, Lundgren JD, et al. A biobehavioural model of the night eating syndrome. Obes Rev. 2009;10:69–77.
   PubMed Web of Science ®Google Scholar
• Funk S. Pharmacological treatment in alcohol-, drug- and benzodiazepine-dependent patients - the significance of trazodone. Neuropsychopharmacol Hung. 2013;15:85–93.
   PubMedGoogle Scholar
• Le Bon O, Murphy JR, Staner L. Double-blind, placebo-controlled study of the efficacy of trazodone in alcohol post-withdrawal syndrome: polysomnographic and clinical evaluations. J Clin Psychopharmacol. 2003;23:377–383.
   PubMed Web of Science ®Google Scholar
• Friedmann PD, Herman DS, Freedman S, et al. Treatment of sleep disturbance in alcohol recovery: a national survey of addiction medicine physicians. J Addict Dis. 2003;22:91–103.
   PubMed Web of Science ®Google Scholar
• Kolla BP, Schneekloth TD, Biernacka JM, et al. Trazodone and alcohol relapse: a retrospective study following residential treatment. Am J Addict. 2011;20:525–529.
   PubMed Web of Science ®Google Scholar
• Anderson SM, Pierce RC. Cocaine-induced alterations in dopamine receptor signaling: implications for reinforcement and reinstatement. Pharmacol Ther. 2005;106:389–403.
   PubMed Web of Science ®Google Scholar
• Rowbotham MC, Jones RT, Benowitz NL, et al. Trazodone-oral cocaine interactions. Arch Gen Psychiatry. 1984;41:895–899.
   PubMed Web of Science ®Google Scholar
• Khouzam HR, Mayo-Smith MF, Bernard DR, et al. Treatment of crack-cocaine-induced compulsive behavior with trazodone. J Subst Abuse Treat. 1995;12:85–88.
   PubMed Web of Science ®Google Scholar
• Chow TW. Treatment approaches to symptoms associated with frontotemporal degeneration. Curr Psychiatry Rep. 2005;7:376–380.
   PubMedGoogle Scholar
• López-Pousa S, Garre-Olmo J, Vilalta-Franch J, et al. Trazodone for Alzheimer’s disease: a naturalistic follow-up study. Arch Gerontol Geriatr. 2008;47:207–215.
   PubMed Web of Science ®Google Scholar
• Fink HA, MacDonald R, Rutks IR, et al. Trazodone for erectile dysfunction: a systematic review and meta-analysis. BJU Int. 2003;92:441–446.
   PubMed Web of Science ®Google Scholar
• Vitezic D, Pelcic JM. Erectile dysfunction: oral pharmacotherapy options. Int J Clin Pharmacol Ther. 2002;40:393–403.
   PubMed Web of Science ®Google Scholar
• Stryjer R, Spivak B, Strous RD, et al. Trazodone for the treatment of sexual dysfunction induced by serotonin reuptake inhibitors: a preliminary open-label study. Clin Neuropharmacol. 2009;32:82–84.
   PubMed Web of Science ®Google Scholar
• Khouzam HR. Psychopharmacology of chronic pain: a focus on antidepressants and atypical antipsychotics. Postgrad Med. 2016;128:323–330.
   PubMed Web of Science ®Google Scholar
• Battistella PA, Ruffilli R, Cernetti R. A placebo-controlled crossover trial using trazodone in pediatric migraine. Headache. 1993;33:36–39.
   PubMed Web of Science ®Google Scholar
• Wilson RC. The use of low-dose trazodone in the treatment of painful diabetic neuropathy. J Am Podiatr Med Assoc. 1999;89:468–471.
   PubMed Web of Science ®Google Scholar
• Morillas-Arques P, Rodriguez-Lopez CM, Molina-Barea R, et al. Trazodone for the treatment of fibromyalgia: an open-label, 12-week study. BMC Musculoskelet Disord. 2010;11:204–209.
   PubMed Web of Science ®Google Scholar
• Starkstein SE, Mizrahi R, Power BD. Antidepressant therapy in post-stroke depression. Expert Opin Pharmacother. 2008;9:1291–1298.
   PubMed Web of Science ®Google Scholar
• Berends HI, Nijlant JM, Movig KL, et al. The clinical use of drugs influencing neurotransmitters in the brain to promote motor recovery after stroke; a cochrane systematic review. Eur J Phys Rehabil Med. 2009;45:621–630.
   PubMed Web of Science ®Google Scholar
• Reding MJ, Orto LA, Winter SW, et al. Antidepressant therapy after stroke. A double-blind trial. Arch Neurol. 1986;43:763–765.
   PubMed Web of Science ®Google Scholar